Connect with us

Featured

Amid Growing Competition, Beyond Meat (BYND) Stock Price Struggles To Sustain At higher Levels

A. Lawrence

Published

on

beyond meat stock price

The market’s freshest technology stocks stumbled on Monday, performing worse than the major indexes and trailing the broader tech sector including Beyond Meat (BYND-Stock Info).

BYND stock faced a deep low after the announcement of news that its counterpart The Meatless Farm has managed to freeze a deal to sell its burgers at Whole Foods in the U.S. With the encroachment of the British rival, the shares of the company fell as much as 10%.

Beyond Meat Shares Slipped With The Arrival Of The Meatless Farm

With a startup in 2009, Beyond Meat which is a Los Angeles-based producer of plant-based meat substitutes has been one among the top performing IPO. However, the arrival of its rival has made the shares of the company go down. There has also been news that Meatless Farm would soon establish an office for operations in the New York City, as the company plans to expand its reach to the U.S. customers.

Read More | Can Marijuana Stocks Benefit From The Growth Of Beyond Meat?

“The market is really hitting up and it is a game changer to be working with Whole Foods Market. The US meat alternative market is currently the largest in the world and is strategically very important for the category.”

According to Rob Woodall, CEO of The Meatless Farm

The US is the fourth market outside of the UK for The Meatless Farm, which was founded in Leeds in 2017. The company also sells its meatless products in Canada, Sweden, and the UAE.

With the intentions of Meatless Farm loud and clear, it is a state of alarm for Beyond Meat. Beyond has so far sustained as the best-performing US IPO. It has also been accredited as the best performer of the year spiking as much as 700% from its offer price. But, with the news of immense competition, the shares of the company dwindled.

Competition Is Growing

While the arched rival Impossible Foods has been successful in working with Burger King, other major companies to enter the race of plant-based meat products are Tyson Foods (TYS-Stock Info) and Nestle (NSRGF-Stock Info). Keeping in mind the sensitivity of the stocks of Beyond Meat after the spilling of the news from Meatless Farm, the growing competition may pose a threat to the shares of Beyond Meat.

[Report] Two Massive Growth Industries, One Choice for Investors

Defending itself from its various competitors, the shares of Beyond Meat saw an upswing with the announcement of new ground beef product. Further, the broadcast of the availability of Beyond breakfast sandwiches at Tim Hortons across Canada helped the company sustain.

In the current scenario, it is difficult to anticipate if Beyond Meat will live up to the hype that’s sent its stock soaring.

Continue Reading
Click to comment

Featured

Roscan (ROS.V) Expands Gold Zone at Mankouke and Makes a New Discovery at Its Kandiole Project in Western Mali

Jon Phillip

Published

on

gold mining stocks to buy

Bedford, Nova Scotia–(Newsfile Corp. – July 22, 2019) – Roscan Gold Corporation (TSXV: ROS) (“Roscan” or the “Company”) is pleased to announce the positive assay results from both its diamond drilling and air core (AC) drilling programs at its Kandiole Project in Mali, West Africa. This drilling program was completed during April to July of 2019 and was designed to test both the north and south extensions of the Mankouke gold discovery zone and many other strong termite and soil, gold anomalies.

[Report] Gold Prices Have Investors Scrambling & Analysts Clamoring For Junior Gold Stocks

The Mankouke gold discovery has been shown, by detailed drilling, to have a strike length of at least 500 metres. In addition, the recent very impressive AC drilling assay results at the southern end of the Mankouke permit, as shown in Figure 1, supports the existence of a 7-kilometer long mineralization target corridor associated with the Mankouke discovery.

Highlights:

In hole ACMan 19-1675.86 g/t Au over 26.0 m (incl. 9.44 g/t Au over 10.0 m)
In hole ACMan 19-1683.74 g/t Au over 30.0 m (incl. 6.73 g/t Au over 6.0 m)
In hole DDH 19-048.63 g/t Au over 10.0 m (incl. 11.48 g/t Au over 7.0 m)
In hole DDH 19-036.53 g/t Au over 5.0 m (incl. 10.09 g/t Au over 3.0 m)
In hole DDH 19-035.56 g/t Au over 3.0 m (incl. 7.14 g/t Au over 2.0 m)
In hole DDH 19-083.45 g/t Au over 10.0 m (incl. 6.76 g/t Au over 3.0 m)

Note: True widths cannot be determined with the information available

A summary of all assay results is presented in Table 1.

COMMENTARY

Greg Isenor, President and CEO of Roscan Gold, stated: “We are continuing to show that we have an excellent new gold discovery at Mankouke that appears to have strike and depth continuity. Our land package has great potential and we are extremely encouraged by the hits we are seeing on the Mankouke permit. There are many assays yet to be received and these will be available in the coming weeks. We are extremely pleased our approach to exploration in this area has been successful. Additional drilling is part of an obvious next step.

The drilling around the Mankouke discovery shows that a strong mineralization system exists and is” alive”. This is not supergene mineralization. We have drilled 19 core holes and have received results for 11 and have significant assays in 8 of the 11 holes. We are waiting for results for both AC and DDH on the north extension of the trend. (See fig 2). Deeper holes are planned when we return to drilling after the rain season. The drilling season is over for a few months, however many results yet to be received. We have the funds to continue drilling after the seasonal rains (July to October). In addition, the excellent AC results we received in the south of the Mankouke permit (see fig 1) will be followed up as soon as possible.

DRILLING PROGRAM

The drilling was carried out during the period May to July with two rigs, one air core drilling rig and one multi-purpose diamond drilling rig. The diamond drilling was completed in the Mankouke discovery zone area and designed to test for extensions to the zone. The drilling program has been suspended until the end of the rainy season. At this point in the drilling program, there has been 19 diamond drill holes completed for a total of 2,017 meters. Assay results have not been received for eight diamond drill holes. See Figure 2.

A total of 607 AC holes were drilled for a total meterage of 28,037 metres. Approximately 60% of the assays of the AC drilling have been received. The AC drilling covered the entire land package with testing the most important termite anomalies. Lines of AC holes were drilled across the target areas generally in an east-west direction and drilled at -50 degrees to the west to a depth of 45 to 60 metres in a heel to toe fashion. AC drilling is used to sample unconsolidated ground with compressed air used to remove the cuttings from the hole. During the Kandiole drilling program, 2 metres long samples were collected. For each 2 metre intersection an ~2-kilogram sample was collected and sent to the laboratory. A check sample of approximately 5 kilograms was collected for possible future tests.

INTREPRETATION

The gold mineralization intersected to date in the Mankouke Zone is hosted in breccia zones which are interbedded with saprolitic metasediments. Recent core holes have intersected gold mineralized breccia (8.63 g/t Au over 10 metres from 79.1 metres to 89.1 metres along the drill hole) at a vertical depth of 60 metres. This drilling indicates that the initially reported gold discovery (News Release January 24, 2019) has “roots” and is not near surface enrichment (supergene). This drilling information clearly shows the potential at depth in this area and identifies that this is typical Birimian, hydrothermal-type gold mineralization.

Additional interpretation will be completed when all data is available.

PLANS

Remaining assays will be received and processed during the rainy season. It is expected that drilling will resume as early as mid-October and will primarily consist of both diamond drilling, to test for both the extensions of the Mankouke gold discovery, and, to test significant AC intersections identified in other areas of the property. In addition, AC drilling will be continued to test the remaining, untested termite and gold soil anomalies.

QUALIFIED PERSON AND SAMPLE PROTOCOL

The technical content in this news release has been reviewed and approved by Gregory P. Isenor, P. Geo, a Qualified Person as defined by NI 43-101.

For quality control, duplicated samples were systematically collected in the field, and blank samples were inserted in the sample batches sent to the laboratory. Before their transportation, the samples were stored in a Roscan secured location in the field. Batches of samples were transported by truck, driven by Roscan contractors, to the Bureau Veritas laboratory sample preparation installation of in Bamako; prepared samples were then shipped by Bureau Veritas to their treatment installation at Abidjan, Ivory Coast. During the assay process, the laboratory applied its own quality controls with blanks, duplicates and standard samples. The assay method was atomic absorption (AA) with pre-concentration by fire assay (FA); the detection limit of the method is of 5 ppb.

ABOUT ROSCAN

Roscan Gold Corporation is a Canadian gold exploration company focused on the acquisition and exploration of gold properties in West Africa. The Company has assembled a significant land position of 100%-owned permits in an area of producing gold mines (including B2 Gold’s Fekola Mine which lies in a contiguous property to the west of Kandiole), and major gold deposits, located both north and south of its Kandiole Project in west Mali.

For further information, please contact:
Greg Isenor
President and Chief Executive Officer
Tel: (902) 832-5555
Email: gpisenor@Roscan.ca

Forward Looking Statements

This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information is characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and other risks involved in the mineral exploration and development industry, including those risks set out in the Company’s management’s discussion and analysis as filed under the Company’s profile at www.sedar.com. Forward-looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary governmental and regulatory approvals will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, other than as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Table 1

SIGNIFICANT ASSAY RESULTS
AIR CORE DRILLING PROGAM 2019

Hole #Line #FROM
(m)
TO
(m)
INTERSECTION
(g/t Au)/m
ACKaN-19-06S 1383715 N2.0
8.0
16.0
30.0
4.0
10.0
18.0
32.0
0.68 g/t Au over 2.0 m
1.05 g/t Au over 2.0 m
0.71 g/t Au over 2.0 m
0.72 g/t Au over 2.0 m
ACMan-19-47S 1379900 N30.032.00.56 g/t Au over 2.0 m
ACMan-19-48S 1379900 N12.014.00.62 g/t Au over 2.0 m
ACMan-19-49S 1379900 N16.022.00.49 g/t Au over 6.0 m
ACMan-19-51


S 1379900 N


2.0
10.0
26.0
4.0
16.0
28.0
1.92 g/t Au over 2.0 m
1.46 g/t Au over 6.0 m

1.34 g/t Au over 2.0 m
ACMan-19-74S 1382160 N34.036.00.51 g/t Au over 2.0 m
ACMan-19-84

S 1380600 N

30.0
46.0
40.0
48.0
1.24 g/t Au over 10.0 m
0.53 g/t Au over 2.0 m
ACMan-19-85S 1380600 N38.044.02.44 g/t Au over 6.0 m
ACMan-19-86

S 1380600 N

12.0
26.0
14.0
30.0
3.10 g/t Au over 2.0 m
4.29 g/t Au over 4.0 m
ACMan-19-88S 1380650 N14.016.03.75 g/t Au over 2.0 m
ACMan-19-89S 1380650 N42.044.00.79 g/t Au over 2.0 m
ACMan-19-90S 1380650 N16.018.02.18 g/t Au over 2.0 m
ACMan-19-155S 1382350 N18.020.02.15 g/t Au over 2.0 m
ACMan-19-163S 1375850 N36.042.01.24 g/t Au over 6.0 m
ACMan-19-165

S 1375850 N

6.0
20.0
10.0
22.0
0.91 g/t Au over 4.0 m
2.37 g/t Au over 2.0 m
ACMan-19-166


S 1375850 N


6.0
30.0
44.0
24.0
34.0
50.0
1.40 g/t Au over 18.0 m
8.14 g/t Au over 4.0 m
6.13 g/t Au over 6.0 m
ACMan-19-167

S 1375850 N




4.0
6.0
24.0
28.0
34.0
20.0
8.0
50.0
30.0
44.0
4.50 g/t Au over 16.0 m
Inc. 23.00 g/t Au over 2.0 m
5.86 g/t Au over 26.0 m
Inc. 10.20 g/t Au over 2.0 m
Inc. 9.44 g/t Au over 10.0 m
ACMan-19-168




S 1375850 N




4.0
10.0
20.0
26.0
46.0
14.0
12.0
50.0
32.0
50.0
3.00 g/t Au over 10.0 m
Inc. 10.60 g/t Au over 2.0 m
3.74 g/t Au over 30.0 m
Inc. 6.73 g/t Au over 6.0 m
Inc. 9.19 g/t Au over 4.0 m
ACMan-19-169



S 1375850 N



0.0
8.0
38.0
38.0
2.0
16.0
50.0
42.0
0.54 g/t Au over 2.0 m
1.34 g/t Au over 8.0 m
3.23 g/t Au over 12.0 m
Inc. 5.92 g/t Au over 4.0 m
ACMan-19-170


S 1375850 N


10.0
10.0
22.0
36.00
12.0
26.0
2.76 g/t Au over 26.0 m
Inc. 6.76 g/t Au over 2.0 m
Inc. 8.74 g/t Au over 4.0 m
ACMan-19-171S 1375850 N6.08.00.64 g/t Au over 2.0 m
ACMan-19-181S 1377200 N4.06.01.31 g/t Au over 2.0 m
ACMan-19-189S 1377200 N26.028.01.01 g/t Au over 2.0 m
ACMan-19-196S 1377200 N4.06.01.59 g/t Au over 2.0 m
ACMan-19-200S 1377420 N22.024.02.10 g/t Au over 2.0 m
ACMan-19-217

S 1377420 N

6.0
16.0
12.0
18.0
1.00 g/t Au over 6.0 m
0.99 g/t Au over 2.0 m
ACMan-19-229S 1378200 N24.026.00.65 g/t Au over 2.0 m
ACMou-19-01S 1398350 N0.02.01.33 g/t Au over 2.0 m
ACMou-19-03

S 1398350 N

12.0
38.0
16.0
40.0
0.81 g/t Au over 4.0 m
0.54 g/t Au over 2.0 m
ACMou-19-08S 1398080 N26.028.00.79 g/t Au over 2.0 m
ACMou-19-10


S 1397290 N


6.0
38.0
42.0
8.0
44.0
44.0
0.52 g/t Au over 2.0 m
3.82 g/t Au over 6.0 m
Inc. 8.46 g/t Au over 2.0 m
ACNia-19-04S 1380260 N20.022.00.64 g/t Au over 2.0 m

Note 1: This table includes all the mineralized intersections with a grade > 0.50 g/t Au; these intersections are considered as significant intersections.

Note 2: Intersections in bold refer to intersections with a grade > 0.50 g/t Au, and a length > 2.0.

Note 3: True widths cannot be determined with the information available.

DIAMOND DRILLING PROGRAM 2019

Hole #Line #FROM
(m)
TO
(m)
INTERSECTION
(g/t Au)/m
DDHMan-19-011380500 N35.0
47.0
39.0
48.0
1.04 g/t Au over 4.0 m
1.97 g/t Au over 1.0 m
DDHMan-19-021380500 N75.177.10.99 g/t Au over 2.0 m
DDHMan-19-031380550 N54.1
54.1
60.1
60.1
71.1
72.1
89.1
57.1
56.1
62.1
61.1
76.1
75.1
90.0
5.56 g/t Au over 3.0 m
Inc. 7.14 g/t Au over 2.0 m
6.48 g/t Au over 2.0 m
Inc. 8.98 g/t Au over 1.0 m
6.53 g/t Au over 5.0 m
Inc. 10.09 g/t Au over 3.0 m
2.60 g/t Au over 0.9 m
DDHMan-19-041380550 N27.1
68.1
79.1
79.1
28.1
72.1
89.1
86.1
1.69 g/t Au over 1.0 m
0.80 g/t Au over 4.0 m
8.63 g/t Au over 10.0 m

Inc. 11.48 g/t Au over 7.0 m
DDHMan-19-051380450 N48.1
51.1
49.1
52.1
1.30 g/t Au over 1.0 m
0.73 g/t Au over 1.0 m
DDHMan-19-071380500 N16.1
28.1
28.1
38.1
17.1
30.1
29.1
39.1
0.71 g/t Au over 1.0 m
14.88 g/t Au over 1.6 m
Inc. 34.00 g/t Au over 0.6 m
0.58 g/t Au over 1.0 m
DDHMan-19-081380600 N11.1
32.1
66.1
73.1
85.1
12.1
33.1
76.1
76.1
86.1
1.07 g/t Au over 1.0 m
12.70 g/t Au over 1.0 m
3.45 g/t Au over 10.0 m
Inc. 6.76 g/t Au over 3.0 m
6.29 g/t Au over 1.0 m
DDHMan-19-121380600 N104.0105.01.07 g/t Au over 1.0 m
DDHMan-19-131380600 N31.0
36.0
41.0
55.0
55.0
74.0
82.0
32.0
37.0
42.0
57.0
56.0
75.0
83.0
0.75 g/t Au over 1.0 m
1.10 g/t Au over 1.0 m
0.64 g/t Au over 1.0 m
4.16 g/t Au over 2.0 m
Inc. 7.81 g/t Au over 1.0 m
0.56 g/t Au over 1.0 m
1.51 g/t Au over 1.0 m

Note 1: This table includes all the mineralized intersections with a grade > 0.50 g/t Au; these intersections are considered as significant intersections.

Note 2: Intersections in bold refer to intersections with a grade > 0.50 g/t Au, and a length > 2.0.

Note 3: True widths cannot be determined with the information available.Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/ea5917b2bb71d8cd5cb3d04eb3e0b297More

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/4821/46368_b01c8377e4b94ae8_001full.jpgCannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/35ccfc69eef57cdc1b5b20a061166663More

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/4821/46368_b01c8377e4b94ae8_002full.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46368

Continue Reading

Featured

Netflix (NFLX) Stock Price Falls After Lower Subs; What Next For Tech Stocks?

Joe Samuel

Published

on

netflix stock price

The streaming leader, Netflix (NFLX) seems to have taken a hit where the subscriber additions are considered. This would be the second time over the last nine quarters that the company has failed to miss on the additions of subscribers by a massive figure of 2.3 million.

Netflix reported for its previous quarter an increase in its revenue by 26% along with an EPS of $0.60. Yet the US subscribers saw a decline by 130,000. Combined with the company’s low profitability and negative cash flows, the stocks of the company may seem to be overvalued. But considering the spending that is being done across the tech sector, this decline may appear a more short term issue. This being said, other technology stocks have been increasing corporate footprints of their own.

Tech Stocks That Could Benefit From The Boom In New Streaming Stocks

The “Netflix and Chill” mentality of the new generation of viewers may have created an opportunity for certain niche sectors. One of these niche’s is on-demand delivery stocks. Amazon and Uber have entered the space with a significant focus on timeliness. However, as Uber puts it, UberEats may be the loss leader for the company due to the infrastructure. Furthermore, Amazon may be more insulated due to the sheer size of its core business.

This being said, it’s vital to look at companies that may be smaller, more nimble, and streamlined for potential profitability. In this regard, ParcelPal (PTNYF) (PKG) has been a company that we’ve discussed numerous times in the past. The company targets on-demand delivery of pretty much anything. But what has set it apart from the UberEats and Postmates of the world is their direct integration of cannabis.

Something that is beginning to set ParcelPal (PTNYF) (PKG) apart from its immediate competition is its diversification strategy. Not only is the company working with the likes of Amazon, but it is also entering into key verticals that are seeing an increase in rapid demand. Right now, ParcelPal (PTNYF) (PKG) has built relationships with businesses in both alcohol and cannabis.

We don’t have to go into the deep details of these booming industries, but it is vital to understand that the evolution from brick-and-mortar to on-demand delivery could be setting the stage for a major economic boom.

While consumers are becoming more comfortable with using smartphones and computers to buy groceries, they are also increasingly using the same technology to help them skip trips to the liquor store, according to data from the e-commerce analytics firm, Slice Intelligence. Netflix and Chill just got an upgrade!

What Does The Future Of Netflix Hold?

Market saturation has become quite a concern for investors. With the current 60.1 million subscribers as compared to the year-ago quarter figure of 55.7 million, it sure is an improvement. However, as per the targets of 60 million to 90 million, as claimed by the company’s CEO Reed Hastings, Netflix barely managed to reach the lower range.

In May, the company implemented a price rise by 18% from US$10.99 to US$12.99 and did not lose much of its customers which is an impressive feat. What also needs to keep in mind is that the previous quarter was relatively light. This is even with blockbuster shows like Stranger Things dropping towards the end of the quarter.

Bigger Costs Could Be Coming; Lower Netflix Stock Price To Follow?

The company also has huge marketing costs it plans to undertake in the later part of 2019. If history serves right then it could bring in enormous subscribers. Previous quarter had seen only a slight increase than a year ago in the marketing expenditure. As compared to quarter including March, the marketing spends actually went down by $13 million.

[FREE REPORT] What Does On-Demand Tech Present To Tech Stock Investors?

Among other worries, content leaving the platform and the rising competition has left the investors anxious. Netflix is losing its most-watched show “The Office” to Comcast. In addition, its second most-watched “Friends” is lost to AT&T. This is happening all while Disney will be taking back its movies – all of which would happen after next year. However, Disney, AT&T, and Comcast are yet to announce their own upcoming streaming services.

It may make it unlikely that consumers are shifting to these platforms. The miss on subscriber additions could be credited to the steep 18% price increase by the company. The light content and marketing also played its part in subscriber additions. The future does not actually seem bleak for the company.

Continue Reading

Biotechnology

PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes

Joe Samuel

Published

on

biotech stocks to watch

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin.

[FULL REPORT] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are pleased to have come to an agreement with UTS that allows us to take the Melligen cells to the next level in our development of a ‘bioartificial pancreas’ for the treatment of Type 1 and insulin-dependent Type 2 diabetes. If we are successful, it will bring to fruition the many years of research that have been conducted by Professor Ann Simpson and her colleagues at UTS as well as PharmaCyte in developing these remarkable insulin-producing cells.”

Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body. PharmaCyte has obtained the exclusive worldwide license rights from UTS to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Box® technology to protect the Melligen cells from immune system attack in the body and thus function as a “bioartificial pancreas” for purposes of insulin production.

The work undertaken by PharmaCyte, UTS and PharmaCyte’s International Diabetes Consortium over the last two years has resulted in an opportunity to re-engineer the Melligen cells with the aim of increasing their insulin production as well as the bioactivity of the produced insulin. With this new agreement in place, the research will be done in Australia under the leadership of Prof. Ann Simpson, the developer of the original Melligen cell line.

The unique properties that set the Melligen cells apart from all other available insulin-producing cell types, include their robustness, their ability to withstand an attack from cell-toxic molecules that typically lead to the destruction of insulin-producing cells and their suitability for cost-efficient pharmacological-grade large scale production. In contrast to primary beta islet cells of the pancreas, which normally produce insulin and stem-cell-derived insulin producing cells, Melligen cells are a scalable and a highly characterized cell line that can readily be expanded in a bioreactor to generate the amounts of cells needed for cell banking, testing and production.

Professor Simpson commented, “We are extremely pleased that we have come to an agreement with PharmaCyte to continue our work on the Melligen cells and advance them to their full potential. Both UTS and PharmaCyte are investing in this important research because we believe in the significant health impact potential. This takes us a step closer to eliminating the need for diabetics to inject insulin daily and, more importantly, protects them from developing the debilitating complications of the disease such as blindness, neuropathy and possible amputations, kidney failure and cardiovascular problems. We look forward to working with PharmaCyte and its International Diabetes Consortium to improve the Melligen cells and to utilize them with the Cell-in-a-Box®encapsulation technology to create a potential cure for diabetes.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

International Diabetes Consortium

PharmaCyte Biotech has established an International Diabetes Consortium (Diabetes Consortium) that consists of world-renowned physicians and scientists from several countries, all of whom share the same goal of developing a treatment for Type 1 and insulin-dependent Type 2 diabetes.

In addition to the Chief Executive Officer, Chief Operating Officer, Chief Scientific Officer and Chief Medical Officer of PharmaCyte, the Diabetes Consortium is made up of well-known physicians and scientists from leading Universities in Munich, Germany, Mannheim, Germany, Vienna, Austria, Barcelona, Spain, Copenhagen, Denmark, and Sydney, Australia. It also involves members from the Karolinska Institute in Stockholm, Sweden, the Vorarlberg Institute for Vascular Investigation and Treatment in Feldkirch, Austria and the biotech company Austrianova in Singapore.

Dr. Eva Maria Brandtner leads the Consortium and is PharmaCyte’s Director of Diabetes Program Development. Dr. Brandtner, who is a consultant for PharmaCyte, previously served as the Chief Scientist with Austrianova. In that role, she conducted preclinical studies with the Melligen cells. Prof. Ann. M Simpson and her colleagues at the University of Technology Sydney developed the Melligen cells. Prof. Simpson is a member of the Consortium.

In addition to key personnel from PharmaCyte, Dr. Brandtner and Prof. Simpson, the Diabetes Consortium includes Prof. Dr. Walter H. Günzburg, the Chief Scientific Officer of PharmaCyte Biotech and the Chief Technical Officer of Austrianova, and Dr. Brian Salmons, the Chief Executive Officer of Austrianova and a member of PharmaCyte’s Medical and Scientific Advisory Board. It also includes research scientists Prof. Dr. Eckhard Wolf and Prof. Dr. Rüdiger Wanke from the Ludwig-Maximillian University (LMU) in Munich, Germany. Both, together with their colleagues at LMU, have developed unique animal models for insulin-dependent diabetes. Other key members of the Diabetes Consortium include Prof. Dr. Hans-Peter Hammes, Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim of Heidelberg University and Section Leader for Endocrinology and Diabetology, Mannheim, Germany, Prof. Dr. Thomas Stratman of the University of Barcelona in Spain and Prof. Dr. Axel Kornerup Hanson of the University of Copenhagen in Denmark.

About University of Technology Sydney

UTS is a dynamic and innovative university in central Sydney. One of Australia’s leading universities of technology, UTS has a distinct model of learning, strong research performance and a leading reputation for engagement with industry and the professions. Based in the vibrant creative and start-up precinct in Ultimo, it has more than 40,000 students and is rated No.1 ‘young’ university in Australia in both the QS and Times Higher Education rankings.

More information about UTS can be found at www.uts.edu .au.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the United States Securities and Exchange Commission.

More information about PharmaCyte can be found at www.PharmaCyte .com. It can also be obtained by contacting Investor Relations.

Contact:Dr. Gerald W. Crabtree 
Investor Relations: 
PharmaCyte Biotech, Inc. 
Investor Relations Department 
Telephone: 917.595.2856 
Email: Info@PharmaCyte. com

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com